Standardized SEC financial data for Merck & Co., Inc. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000310158 · NYSE · Pharmaceutical Preparations.
Ratios for fiscal year 2025, standardized from SEC filings.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $41.52B | $48.70B | $59.28B | $60.12B | $64.17B | $65.01B |
| Cost of revenue | $13.62B | $13.63B | $17.41B | $16.13B | $15.19B | $16.38B |
| Gross profit | $27.90B | $35.08B | $41.87B | $43.99B |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.15B | $8.17B | $12.77B | $6.91B | $13.32B | $14.69B |
| Inventory | $7.71B | $8.16B | $9.14B | $10.27B | $11.14B | $13.25B |
| Total current assets | $27.76B | $30.27B | $35.72B | $32.17B |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $10.25B | $13.12B | $19.09B | $13.01B | $21.47B | $16.47B |
| Capital expenditures | $4.43B | $4.45B | $4.39B | $3.86B | $3.37B | $4.11B |
| Free cash flow | $5.82B | $8.67B | $14.71B | $9.14B |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/MRK/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/MRK/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $48.98B |
| $48.63B |
| R&D expense | $13.40B | $12.24B | $13.55B | $30.53B | $17.94B | $15.79B |
| SG&A expense | $8.96B | $9.63B | $10.04B | $10.50B | $10.82B | $10.73B |
| Interest expense | $831.0M | $806.0M | $962.0M | $1.15B | $1.30B | $1.30B |
| Pretax income | $5.86B | $13.88B | $16.44B | $1.89B | $19.94B | $21.07B |
| Income tax | $1.34B | $1.52B | $1.92B | $1.51B | $2.80B | $2.80B |
| Net income | $7.07B | $13.05B | $14.52B | $365.0M | $17.12B | $18.25B |
| EPS (diluted) | $2.78 | $5.14 | $5.71 | $0.14 | $6.74 | $7.28 |
Standardized from Merck & Co., Inc.'s SEC filings — per-share figures split-adjusted. Full history via the API.
| $38.78B |
| $43.52B |
| Property, plant & equipment | $17.00B | $19.28B | $21.42B | $23.05B | $23.78B | $25.32B |
| Goodwill | $18.88B | $21.26B | $21.20B | $21.20B | $21.67B | $21.58B |
| Total assets | $91.59B | $105.69B | $109.16B | $106.67B | $117.11B | $136.87B |
| Total current liabilities | $27.33B | $23.87B | $24.24B | $25.69B | $28.42B | $28.33B |
| Long-term debt | $25.36B | $30.69B | $28.75B | $33.68B | $34.46B | $46.75B |
| Total debt | $27.66B | $32.99B | $30.45B | $34.98B | $36.96B | $49.05B |
| Total liabilities | $66.18B | $67.44B | $63.10B | $69.04B | $70.73B | $84.20B |
| Retained earnings | $47.36B | $53.70B | $61.08B | $53.90B | $63.07B | $73.08B |
| Total equity | $25.40B | $38.26B | $46.06B | $37.63B | $46.37B | $52.66B |
| $18.10B |
| $12.36B |
| Investing cash flow | -$9.44B | -$16.42B | -$4.96B | -$14.08B | -$7.73B | -$13.74B |
| Financing cash flow | -$2.83B | $3.10B | -$9.12B | -$4.81B | -$7.03B | -$1.92B |
| Dividends paid | $6.31B | $6.71B | $7.13B | $7.55B | $7.94B | $8.25B |
| Share repurchases | $1.28B | $840.0M | $0 | $1.35B | $1.31B | $5.08B |